Women’s Health Solutions
Women's Health Solutions
Latest posts by Dr. Zahra Aghanouri, MD, PhD (see all)
- Are You Sleep Deficient? Find Your Herbal Sleep Aid Quiz - July 2, 2025
- The Truth About Women’s Hormones - June 29, 2025
- Cornmeal (Zea mays) - December 23, 2024
A Comprehensive Guide to Wellness and Care
Introduction: Understanding Women’s Health
Women’s health encompasses a broad spectrum of physical, mental, and social well-being concerns that affect women throughout their lifespan. From reproductive and hormonal health to gender-specific disease risks and psychosocial factors, women face unique health challenges that require specialized attention and care [1]. While significant advances have been made in understanding and addressing women’s health issues, disparities in research, treatment, and healthcare access continue to exist [2].
This comprehensive guide explores key aspects of women’s health, including reproductive health, menopausal transitions, preventive care, and emerging research. By understanding these topics in depth, women can make informed decisions about their health and advocate for appropriate care throughout all life stages.
Reproductive Health: From Planning to Pregnancy
Reproductive health forms a cornerstone of women’s overall well-being, encompassing family planning, fertility, pregnancy, and related conditions.
Family Planning and Contraception
Family planning allows women to choose if and when to have children, supporting autonomy and health. Modern contraceptive options include:
•Hormonal Methods: Including combined oral contraceptives, progestin-only pills, patches, vaginal rings, and injectable contraceptives. These methods work primarily by preventing ovulation and creating cervical mucus changes that inhibit sperm movement [3].
•Long-Acting Reversible Contraceptives (LARCs): Including intrauterine devices (IUDs) and implants, which provide highly effective contraception for 3-10 years without requiring daily attention [4].
•Barrier Methods: Including condoms, diaphragms, and cervical caps, which physically prevent sperm from reaching an egg and may provide protection against sexually transmitted infections [5].
•Natural Family Planning: Methods based on tracking fertility signs to avoid or achieve pregnancy, including symptothermal methods, ovulation prediction kits, and fertility awareness apps [6].
Women with chronic conditions require special consideration when choosing contraception. For instance, women with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) should discuss family planning as early as possible after diagnosis [7]. Most can have successful pregnancies with proper risk assessment and management, considering factors such as disease activity, autoantibody profile, previous complications, hypertension, and medication use. Hormonal contraception can be used in stable/inactive disease with low thrombosis risk, and fertility preservation with gonadotropin-releasing hormone analogues should be considered before immunosuppressant use [8].
Assisted Reproduction
For women experiencing fertility challenges, assisted reproductive technologies (ART) offer potential pathways to pregnancy:
•In Vitro Fertilization (IVF): Involves stimulating the ovaries to produce multiple eggs, retrieving them for fertilization in a laboratory, and transferring resulting embryos to the uterus [9].
•Intrauterine Insemination (IUI): Involves placing specially prepared sperm directly into the uterus around the time of ovulation [10].
•Egg Freezing (Oocyte Cryopreservation): Allows women to preserve fertility by freezing eggs for potential future use, particularly valuable for those facing cancer treatment or wishing to delay childbearing [11].
Women with autoimmune conditions can generally use these technologies safely when their disease is stable or inactive. For instance, patients with positive antiphospholipid antibodies or APS should receive anticoagulation and/or low-dose aspirin during treatment [12]. Careful monitoring of disease activity, renal function, and serological markers is essential throughout the process.
Pregnancy Management
Pregnancy represents a unique physiological state requiring specialized care and monitoring:
•Preconception Care: Includes optimizing health before pregnancy through appropriate vaccinations, folic acid supplementation, management of chronic conditions, and lifestyle modifications [13].
•Prenatal Care: Regular check-ups to monitor maternal and fetal health, including screenings for gestational diabetes, preeclampsia, and fetal anomalies [14].
•High-Risk Pregnancy Management: Specialized care for women with pre-existing conditions or pregnancy complications, often involving a multidisciplinary team approach [15].
For women with autoimmune conditions like SLE or APS, pregnancy requires particularly close monitoring. Assessment of disease activity, renal function, and serological markers is crucial for detecting flares and obstetrical complications [16]. Fetal monitoring includes Doppler ultrasonography and biometry, particularly in the third trimester, to screen for placental insufficiency and growth restriction [17]. Preventive measures can significantly reduce the risks of adverse maternal or fetal outcomes.
Menopausal Health: Navigating the Transition
Menopause, defined as the cessation of menstruation for 12 consecutive months, typically occurs between ages 45-55 and represents a significant transition in women’s lives [18]. The perimenopausal period leading up to menopause can last several years and is characterized by hormonal fluctuations that may cause various symptoms.
Understanding Menopause
The menopausal transition involves several stages:
•Perimenopause: The period leading up to menopause, characterized by irregular menstrual cycles and fluctuating hormone levels, typically beginning in a woman’s 40s [19].
•Menopause: Officially diagnosed after 12 consecutive months without a menstrual period, marking the end of reproductive capability [20].
•Postmenopause: The period following menopause, during which women may experience long-term effects of estrogen deficiency [21].
Common symptoms during this transition include:
•Vasomotor symptoms (hot flashes and night sweats)
•Sleep disturbances
•Mood changes
•Vaginal dryness and sexual discomfort
•Changes in cognitive function
•Joint pain
•Urinary symptoms [22]
The severity and duration of these symptoms vary widely among women, influenced by factors including genetics, lifestyle, and cultural context [23].
Menopausal Hormone Therapy (MHT)
MHT, including estrogen-alone therapy (ET) and estrogen plus progestin therapy (EPT), has a complex balance of benefits and risks that must be carefully considered for each woman [24].
Benefits of MHT include:
•Relief of vasomotor symptoms (hot flashes and night sweats)
•Prevention of bone loss and reduction of fracture risk
•Improvement in sleep quality
•Reduced risk of diabetes mellitus
•Potential reduction in cardiovascular mortality (with ET)
•Potential reduction in colorectal cancer risk (with EPT) [25]
Risks of MHT include:
•Increased risk of stroke
•Increased risk of venous thromboembolism
•Potential increased risk of cardiovascular disease incidence and recurrence
•Increased risk of gallbladder disease requiring surgery
•Potential increased risk of breast cancer (particularly with EPT)
•Potential increased risk of lung cancer mortality (with EPT) [26]
The effects of ET and EPT differ for endometrial cancer, endometrial hyperplasia, and cognitive function [27]. Women with an intact uterus must use EPT rather than ET alone to prevent endometrial hyperplasia and cancer [28].
Considerations for MHT Use
The decision to use MHT should be individualized based on:
•Age and time since menopause onset
•Symptom severity and impact on quality of life
•Personal medical history and risk factors
•Family history
•Personal preferences and values [29]
The benefits and risks vary depending on the type, dose, formulation, duration of use, route of administration, and age of initiation [30]. Current guidelines generally support the use of MHT for symptom management in women without contraindications who are within 10 years of menopause onset or under age 60 [31]. However, MHT is not recommended solely for chronic disease prevention based on evidence from the Women’s Health Initiative randomized trials [32].
Non-Hormonal Approaches to Menopause Management
For women who cannot or choose not to use MHT, several non-hormonal options exist:
•Lifestyle Modifications: Regular physical activity, maintaining healthy weight, stress reduction techniques, and avoiding triggers (like alcohol, caffeine, and spicy foods) can help manage vasomotor symptoms [33].
•Dietary Supplements: Some women find relief with supplements like black cohosh, red clover, or soy isoflavones, though evidence for efficacy is mixed and quality control can be a concern [34].
•Prescription Medications: Certain antidepressants (SSRIs/SNRIs), gabapentin, and clonidine have shown efficacy for hot flash management [35].
•Cognitive Behavioral Therapy: Can help women develop coping strategies for managing menopausal symptoms and associated stress [36].
•Vaginal Treatments: For genitourinary symptoms, options include vaginal moisturizers, lubricants, and low-dose vaginal estrogen preparations with minimal systemic absorption [37].
Women’s Health Research and Innovation: Addressing the Gap
Despite comprising approximately half the global population, women have historically been underrepresented in medical research, leading to knowledge gaps in understanding female-specific health conditions and sex differences in disease presentation and treatment response [38].
Gender Disparities in Medical Research and Innovation
Several factors contribute to the research gap in women’s health:
•Historical Exclusion: Women were routinely excluded from clinical trials until the 1990s, when policy changes mandated their inclusion [39].
•Funding Disparities: There is a documented disparity between the preclinical funding and disease burden for women-specific disorders compared to men-specific disorders. For almost 75% of disorders that affect primarily one gender, US federal funding favors men [40].
•Gender Gap in Innovation: Women engage in less commercial patenting and invention compared to men, which may affect the diversity of inventions. Patents by all-female inventor teams are 35% more likely than all-male teams to focus on women’s health, suggesting that the gender gap in invention may be partially responsible for the lack of female-focused innovations [41].
•Complex Considerations: Women’s health research must also consider the complex social sensitivities in reproductive health and the mother-fetus as a single entity, which can present additional challenges [42].
Improving Women’s Health Research
Several strategies can help address these disparities:
•Sex-Specific Analysis: Requiring researchers to analyze and report results by sex to identify potential differences in disease mechanisms, symptoms, and treatment responses [43].
•Inclusive Clinical Trials: Ensuring appropriate representation of women in clinical trials, including those of reproductive age, pregnant women (when appropriate), and diverse racial and ethnic backgrounds [44].
•Targeted Funding: Increasing funding for research on conditions that predominantly affect women and for understanding sex differences in common conditions [45].
•Appropriate Preclinical Models: Developing and utilizing preclinical models that accurately reflect female physiology, considering the physiological and pathophysiological differences amongst species [46].
•Leveraging Existing Technologies: The engineering of delivery systems for women’s health can build on delivery technologies that have shown clinical success in other disease applications, with careful attention to safety and toxicity considerations [47].
Emerging Areas in Women’s Health Research
Several promising research areas are advancing our understanding of women’s health:
•Precision Medicine: Tailoring prevention, diagnosis, and treatment strategies based on individual genetic, environmental, and lifestyle factors, with attention to sex-specific factors [48].
•Digital Health Technologies: Utilizing mobile health apps, wearable devices, and telehealth to improve access to care, monitor conditions, and empower women in health management [49].
•Microbiome Research: Investigating the role of the vaginal, gut, and other microbiomes in women’s health conditions, including reproductive tract infections, preterm birth, and gynecological cancers [50].
•Non-Invasive Diagnostics: Developing less invasive methods for diagnosing and monitoring conditions like endometriosis, which currently requires surgical diagnosis [51].
•Regenerative Medicine: Exploring applications for conditions like stress urinary incontinence, pelvic organ prolapse, and reproductive tissue engineering [52].
Common Women’s Health Concerns: Prevention and Management
Women face several health conditions that occur exclusively in females or at higher rates compared to men, requiring specific attention and approaches.
Reproductive System Disorders
•Endometriosis: Affects approximately 10% of reproductive-age women, causing pelvic pain, heavy menstrual bleeding, and potential fertility issues. Management includes hormonal therapies, pain management, and surgical interventions when necessary [53].
•Polycystic Ovary Syndrome (PCOS): A common hormonal disorder affecting 8-13% of reproductive-age women, characterized by irregular periods, elevated androgens, and polycystic ovaries. Management focuses on symptom relief, metabolic health, and fertility support when desired [54].
•Uterine Fibroids: Benign tumors that develop in or around the uterus, affecting up to 70% of women by age 50. Treatment options range from medication to minimally invasive procedures to surgery, depending on symptom severity and reproductive goals [55].
•Gynecological Cancers: Including cervical, ovarian, uterine, vaginal, and vulvar cancers. Prevention strategies include HPV vaccination, regular screening, and awareness of symptoms for early detection [56].
Autoimmune Conditions
Women are more susceptible to many autoimmune diseases, including:
•Systemic Lupus Erythematosus (SLE): Affects women 9 times more frequently than men, with peak incidence during reproductive years. Management includes immunosuppressive medications, antimalarials, and careful monitoring, particularly during pregnancy [57].
•Rheumatoid Arthritis (RA): Affects approximately 1% of the population, with women 2-3 times more likely to develop RA than men. Treatment focuses on disease-modifying antirheumatic drugs to control inflammation and prevent joint damage [58].
•Hashimoto’s Thyroiditis: The most common cause of hypothyroidism, affecting women 7 times more frequently than men. Management typically involves thyroid hormone replacement therapy [59].
•Multiple Sclerosis (MS): Affects women 2-3 times more frequently than men. Treatment includes disease-modifying therapies to reduce relapses and slow progression [60].
The higher prevalence of autoimmune conditions in women is thought to be related to sex hormones, X chromosome effects, and differences in immune system function [61].
Cardiovascular Health
While often considered a “men’s disease,” cardiovascular disease is the leading cause of death in women worldwide [62]. Women may experience different symptoms of heart disease than men and face unique risk factors:
•Sex-Specific Risk Factors: Include pregnancy complications (preeclampsia, gestational diabetes), premature menopause, and certain autoimmune disorders [63].
•Symptom Differences: Women may experience less typical symptoms of heart attack, such as fatigue, shortness of breath, and back or jaw pain, rather than the classic chest pain [64].
•Prevention Strategies: Include regular screening for traditional risk factors (hypertension, diabetes, cholesterol), maintaining healthy weight, regular physical activity, and smoking cessation [65].
Mental Health
Women experience certain mental health conditions at higher rates than men, including:
•Depression: Women are approximately twice as likely as men to experience depression, with hormonal fluctuations, life stressors, and societal factors contributing to this disparity [66].
•Anxiety Disorders: More prevalent in women, with potential links to hormonal fluctuations, socialization differences, and trauma exposure [67].
•Perinatal Mood Disorders: Including prenatal and postpartum depression and anxiety, affecting up to 20% of women during pregnancy and the postpartum period [68].
•Eating Disorders: Disproportionately affect women, with complex biological, psychological, and sociocultural contributing factors [69].
Addressing women’s mental health requires consideration of sex-specific biological factors, gender-related psychosocial influences, and life stage transitions [70].
Preventive Care and Wellness Strategies for Women
Preventive care is essential for maintaining health and detecting potential issues early when they are most treatable.
Recommended Screenings by Age
•Ages 18-39:
•Annual well-woman visit
•Blood pressure screening
•Cervical cancer screening (Pap test every 3 years beginning at age 21)
•Chlamydia and gonorrhea screening for sexually active women
•HIV and other STI screening based on risk factors
•Depression screening [71]
•Ages 40-64:
•All previous screenings
•Mammography (recommendations vary by organization, generally beginning at age 40-50)
•Colorectal cancer screening beginning at age 45-50
•Diabetes screening
•Lipid panel for cholesterol screening
•Bone density screening for women at risk [72]
•Ages 65 and older:
•All previous screenings as appropriate
•Bone density screening for osteoporosis
•Hearing and vision screening
•Screening for elder abuse
•Cognitive assessment [73]
Nutrition and Physical Activity
Women have specific nutritional needs that change throughout the lifespan:
•Key Nutrients: Women need adequate calcium and vitamin D for bone health, iron to replace menstrual losses, folate (especially before and during pregnancy), and omega-3 fatty acids for heart and brain health [74].
•Physical Activity Recommendations: At least 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous activity weekly, plus muscle-strengthening activities at least twice weekly [75].
•Life Stage Considerations: Nutritional needs change during pregnancy, lactation, perimenopause, and postmenopause, requiring adjustments to dietary intake [76].
Stress Management and Self-Care
Chronic stress can negatively impact physical and mental health, making stress management an important component of women’s wellness:
•Mindfulness and Meditation: Regular practice can reduce stress, anxiety, and depression while improving focus and emotional regulation [77].
•Adequate Sleep: Prioritizing 7-9 hours of quality sleep supports immune function, hormone balance, cognitive function, and emotional well-being [78].
•Social Connection: Maintaining meaningful relationships provides emotional support and has been linked to better health outcomes and longevity [79].
•Setting Boundaries: Learning to say no and establishing healthy boundaries in personal and professional relationships can prevent burnout and reduce stress [80].
Herbal and Natural Approaches to Women’s Health
Many women seek natural approaches to support health and manage symptoms:
•Adaptogenic Herbs: Herbs like ashwagandha, rhodiola, and holy basil may help the body adapt to stress and support adrenal function [81].
•Hormone-Balancing Herbs: Plants like chaste tree berry (Vitex), black cohosh, and dong quai have traditionally been used to support hormonal balance and manage symptoms related to menstruation and menopause [82].
•Anti-Inflammatory Herbs: Turmeric, ginger, and boswellia may help manage inflammation associated with conditions like endometriosis and autoimmune disorders [83].
•Cognitive Support: Herbs like ginkgo biloba, bacopa, and gotu kola may support cognitive function and mental clarity during hormonal transitions [84].
When considering herbal approaches, it’s important to consult with healthcare providers, particularly when taking medications or managing chronic conditions, as herbs can interact with conventional treatments [85].
Conclusion: Advocating for Women’s Health
Women’s health is a complex and evolving field that requires attention to biological, psychological, and social factors across the lifespan. By understanding the unique aspects of women’s health and advocating for appropriate care, women can make informed decisions that support their well-being at every stage of life.
Key takeaways include:
•The importance of regular preventive care and appropriate screenings
•The need for individualized approaches to health management, particularly during hormonal transitions
•The value of addressing both physical and mental health as interconnected aspects of overall well-being
•The ongoing need for research and innovation to address gaps in women’s health knowledge and care
As research continues to advance our understanding of women’s health, healthcare approaches will continue to evolve, offering more personalized and effective strategies for prevention, diagnosis, and treatment.
References
[1] Clayton JA, Tannenbaum C. Reporting sex, gender, or both in clinical research? JAMA. 2016;316(18):1863-1864.
[2] Mazure CM, Jones DP. Twenty years and still counting: including women as participants and studying sex and gender in biomedical research. BMC Womens Health. 2015;15:94.
[3] Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016;65(3):1-103.
[4] Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998-2007.
[5] Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397-404.
[6] Manhart MD, Duane M, Lind A, et al. Fertility awareness-based methods of family planning: A review of effectiveness for avoiding pregnancy using SORT. Osteopath Fam Physician. 2013;5(1):2-8.
[7] Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-485.
[8] Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020;72(4):529-556.
[9] Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(1):37-43.
[10] ESHRE Capri Workshop Group. Intrauterine insemination. Hum Reprod Update. 2009;15(3):265-277.
[11] Cobo A, García-Velasco JA, Coello A, et al. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105(3):755-764.e8.
[12] Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-485.
[13] Johnson K, Posner SF, Biermann J, et al. Recommendations to improve preconception health and health care–United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. MMWR Recomm Rep. 2006;55(RR-6):1-23.
[14] American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 649: Racial and Ethnic Disparities in Obstetrics and Gynecology. Obstet Gynecol. 2015;126(6):e130-e134.
[15] Kilpatrick SJ, Papile LA, Macones GA, eds. Guidelines for Perinatal Care. 8th ed. American Academy of Pediatrics and American College of Obstetricians and Gynecologists; 2017.
[16] Buyon JP, Kim MY, Guerra MM, et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med. 2015;163(3):153-163.
[17] Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-485.
[18] Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159-1168.
[19] Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015;44(3):497-515.
[20] Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159-1168.
[21] Monteleone P, Mascagni G, Giannini A, et al. Symptoms of menopause – global prevalence, physiology and implications. Nat Rev Endocrinol. 2018;14(4):199-215.
[22] Freeman EW, Sammel MD, Lin H, et al. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol. 2011;117(5):1095-1104.
[23] Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539.
[24] The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753.
[25] Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318(10):927-938.
[26] Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368.
[27] The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753.
[28] Furness S, Roberts H, Marjoribanks J, et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012;(8):CD000402.
[29] The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753.
[30] Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318(10):927-938.
[31] The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753.
[32] Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368.
[33] Daley A, Stokes-Lampard H, Thomas A, et al. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2014;(11):CD006108.
[34] Franco OH, Chowdhury R, Troup J, et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA. 2016;315(23):2554-2563.
[35] Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22(11):1155-1174.
[36] Green SM, Haber E, McCabe RE, et al. Cognitive-behavioral group treatment for menopausal symptoms: a systematic review and meta-analysis. Climacteric. 2017;20(2):124-133.
[37] Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902.
[38] Mazure CM, Jones DP. Twenty years and still counting: including women as participants and studying sex and gender in biomedical research. BMC Womens Health. 2015;15:94.
[39] Liu KA, Mager NA. Women’s involvement in clinical trials: historical perspective and future implications. Pharm Pract (Granada). 2016;14(1):708.
[40] Mirin AA. Gender disparity in the funding of diseases by the U.S. National Institutes of Health. J Womens Health (Larchmt). 2021;30(7):956-963.
[41] Koning R, Samila S, Ferguson JP. Who do we invent for? Patents by women focus more on women’s health, but few women get to invent. Science. 2021;372(6548):1345-1348.
[42] Bianchi DW, Kaeser L, Cernich AN. Involving pregnant individuals in clinical research on COVID-19 vaccines. JAMA. 2021;325(11):1041-1042.
[43] Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature. 2014;509(7500):282-283.
[44] Liu KA, Mager NA. Women’s involvement in clinical trials: historical perspective and future implications. Pharm Pract (Granada). 2016;14(1):708.
[45] Mirin AA. Gender disparity in the funding of diseases by the U.S. National Institutes of Health. J Womens Health (Larchmt). 2021;30(7):956-963.
[46] Blum KA, Thakor AS, Hetts SW, et al. Optimizing the design and development of biomaterials and devices for women’s health. Adv Mater. 2021;33(43):e2007879.
[47] Blum KA, Thakor AS, Hetts SW, et al. Optimizing the design and development of biomaterials and devices for women’s health. Adv Mater. 2021;33(43):e2007879.
[48] Precision Medicine Initiative Working Group. The Precision Medicine Initiative Cohort Program – Building a Research Foundation for 21st Century Medicine. National Institutes of Health; 2015.
[49] Lupton D. Quantifying the body: monitoring and measuring health in the age of mHealth technologies. Crit Public Health. 2013;23(4):393-403.
[50] Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4680-4687.
[51] Agarwal SK, Chapron C, Giudice LC, et al. Clinical diagnosis of endometriosis: a call to action. Am J Obstet Gynecol. 2019;220(4):354.e1-354.e12.
[52] Ulrich D, Edwards SL, Su K, et al. Human endometrial mesenchymal stem cells modulate the tissue response and mechanical behavior of polyamide mesh implants for pelvic organ prolapse repair. Tissue Eng Part A. 2014;20(3-4):785-798.
[53] Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020;382(13):1244-1256.
[54] Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-1618.
[55] Stewart EA, Cookson CL, Gandolfo RA, et al. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501-1512.
[56] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
[57] Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017;56(11):1945-1961.
[58] Hunter TM, Boytsov NN, Zhang X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int. 2017;37(9):1551-1557.
[59] Ragusa F, Fallahi P, Elia G, et al. Hashimoto’s thyroiditis: epidemiology, pathogenesis, clinic and therapy. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101367.
[60] Harbo HF, Gold R, Tintoré M. Sex and gender issues in multiple sclerosis. Ther Adv Neurol Disord. 2013;6(4):237-248.
[61] Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35(3):347-369.
[62] Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-e596.
[63] Mehta LS, Beckie TM, DeVon HA, et al. Acute myocardial infarction in women: a scientific statement from the American Heart Association. Circulation. 2016;133(9):916-947.
[64] Mehta LS, Beckie TM, DeVon HA, et al. Acute myocardial infarction in women: a scientific statement from the American Heart Association. Circulation. 2016;133(9):916-947.
[65] Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243-1262.
[66] Albert PR. Why is depression more prevalent in women? J Psychiatry Neurosci. 2015;40(4):219-221.
[67] McLean CP, Asnaani A, Litz BT, et al. Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res. 2011;45(8):1027-1035.
[68] Gavin NI, Gaynes BN, Lohr KN, et al. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005;106(5 Pt 1):1071-1083.
[69] Striegel-Moore RH, Bulik CM. Risk factors for eating disorders. Am Psychol. 2007;62(3):181-198.
[70] Kuehner C. Why is depression more common among women than among men? Lancet Psychiatry. 2017;4(2):146-158.
[71] US Preventive Services Task Force. Published Recommendations. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics
[72] US Preventive Services Task Force. Published Recommendations. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics
[73] US Preventive Services Task Force. Published Recommendations. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics
[74] Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. The National Academies Press; 2011.
[75] Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans. JAMA. 2018;320(19):2020-2028.
[76] Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. The National Academies Press; 2005.
[77] Goyal M, Singh S, Sibinga EM, et al. Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. JAMA Intern Med. 2014;174(3):357-368.
[78] Watson NF, Badr MS, Belenky G, et al. Recommended amount of sleep for a healthy adult: a joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep. 2015;38(6):843-844.
[79] Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med. 2010;7(7):e1000316.
[80] Maslach C, Leiter MP. Understanding the burnout experience: recent research and its implications for psychiatry. World Psychiatry. 2016;15(2):103-111.
[81] Panossian A, Wikman G. Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. Pharmaceuticals (Basel). 2010;3(1):188-224.
[82] van Die MD, Burger HG, Teede HJ, et al. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med. 2013;79(7):562-575.
[83] Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92.
[84] Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013;16(4):313-326.
[85] Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13):1777-1798.
